

Remarks

Claims 1-26 were pending. Claims 15-17 are cancelled. No claims are added.
Therefore, claims 1-14 and 18-26 are now pending.


By this amendment, the specification was amended to incorporate Applicants' claim of priority, and to include a sequence listing and an abstract. The title of the invention was amended to correct the English translation of the Japanese application.

The claims were amended to remove multiple dependencies. In addition, claims 22 and 23 are amended to clarify that the polynucleotide is an isolated polynucleotide.

No new matter is added by this amendment, and no amendments are made to distinguish prior art. If there are any questions regarding this amendment, the Examiner is invited to telephone the undersigned.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By 
Sheree Lynn Rybak, Ph.D.
Registration No. 47,913

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 228-9446